Dosimetric Consequences of 3D Versus 4D PET/CT for Target Delineation of Lung Stereotactic Radiotherapy
Conclusions: Target delineation using 3D PET/CT without additional respiratory compensation techniques results in significant target underdosing in the context of SABR. (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - June 25, 2015 Category: Cancer & Oncology Tags: Brief Reports Source Type: research
VAMP2–NRG1 Fusion Gene is a Novel Oncogenic Driver of Non–Small-Cell Lung Adenocarcinoma
Conclusion: VAMP2–NRG1 is a novel oncogenic fusion gene representing a new addition to the list of NRG1 fusion genes, which together may form an important diagnostic and clinical category of lung adenocarcinoma cases. (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - June 25, 2015 Category: Cancer & Oncology Tags: Brief Reports Source Type: research
Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer
Conclusions: PFS demonstrated strong surrogacy for OS in first-line ES-SCLC based on this external validation study of individual patient data. PFS is a good alternative end point to OS and should be considered when resource constraints (time or patient) might make it useful or desirable in place of OS. Additional analyses are needed to assess its appropriateness for targeted agents in this disease setting. (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - June 25, 2015 Category: Cancer & Oncology Tags: Original Articles Source Type: research
Proposed Modification of Nodal Staging as an Alternative to the Seventh Edition of the American Joint Committee on Cancer Tumor-Node-Metastasis Staging System Improves the Prognostic Prediction in the Resected Esophageal Squamous-Cell Carcinoma
Conclusions: The modified staging system with the revised N categories based on the number of LNs metastasis stations better predicts the survival of Chinese ESCC population than the 7th AJCC staging system. Further studies are required to confirm this result. (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - June 25, 2015 Category: Cancer & Oncology Tags: Original Articles Source Type: research
Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer
Conclusions: A subset of SCLCs is characterized by potentially activated FGF/FGFR1 pathways, as evidenced by positive FGF2, FGF9, and FGFR1 protein and/or mRNA expression. FGFR1 protein expression is correlated with FGFR1 mRNA levels and FGFR1 gene copy number. Combined analysis of FGFR1 and ligand expression may allow selection of patients with SCLC to FGFR1 inhibitor therapy. (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - June 25, 2015 Category: Cancer & Oncology Tags: Original Articles Source Type: research
Surgical Intervention for Non–Small-Cell Lung Cancer Patients with Pleural Carcinomatosis: Results From the Japanese Lung Cancer Registry in 2004
Conclusion: In our surgical registry for NSCLC, patients with pleural carcinomatosis accounted for 2.9%, and macroscopic complete resection for them was associated with better survival. (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - June 25, 2015 Category: Cancer & Oncology Tags: Original Articles Source Type: research
Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I–III Non–Small-Cell Lung Cancer
Conclusions: The functional FLT1 variant rs9582036 is a prognostic determinant of recurrence in stage I–III NSCLC. Its predictive value should be tested in the adjuvant setting of stage I–III NSCLC. (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - June 25, 2015 Category: Cancer & Oncology Tags: Original Articles Source Type: research
Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non–Small-Cell Lung Cancer or Other Tumors
Conclusions: Ceritinib maximum-tolerated dose was 750 mg once daily in Japanese patients. Antitumor activity was observed irrespective of prior ALKi treatment history. Dose expansion, examining the activity of ceritinib in alectinib-resistant patients, is ongoing. (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - June 25, 2015 Category: Cancer & Oncology Tags: Original Articles Source Type: research
Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients
Conclusion: Overall, our data demonstrate the utility of systematic sequencing analysis in a clinical routine setting and highlight the dramatic impact of such an approach on the availability of therapeutic strategies for the targeted treatment of individual cancer patients. (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - June 25, 2015 Category: Cancer & Oncology Tags: Original Articles Source Type: research
An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers
Conclusion: A prognostic classifier comprising three types of genomic and epigenomic data may help guide the postoperative management of stage I lung cancer patients at high risk of recurrence. (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - June 25, 2015 Category: Cancer & Oncology Tags: Original Articles Source Type: research
Combination Treatment with All-Trans Retinoic Acid Prevents Cisplatin-Induced Enrichment of CD133+ Tumor-Initiating Cells and Reveals Heterogeneity of Cancer Stem Cell Compartment in Lung Cancer
In this study, we report, by in vitro cell fate tracing systems, heterogeneity within the TIC compartment with a highly quiescent pool and a slowly dividing subpopulation, both containing CD133+ cells but respectively enriched for CD133+/CXCR4− and CD133+/CXCR4+ cells. Pretreatment with differentiating agent all-trans retinoic acid counteracts cisplatin resistance specifically of the slowly dividing compartment indicating effect on CD133+/CXCR4+ cells. The same effects are appreciable also in vivo in patient-derived xenografts, where several cycles of all-trans retinoic acid and cisplatin treatment are able to stably red...
Source: Journal of Thoracic Oncology - June 25, 2015 Category: Cancer & Oncology Tags: Original Articles Source Type: research
Association of PDCD1 and CTLA-4 Gene Expression with Clinicopathological Factors and Survival in Non–Small-Cell Lung Cancer: Results from a Large and Pooled Microarray Database
Conclusions: In this study with large number of patients, PDCD1 and CTLA-4 expression is significantly higher in squamous carcinoma and current/former smokers. Higher expression of CTLA-4, but not PDCD1 predicts worse survival. (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - June 25, 2015 Category: Cancer & Oncology Tags: Original Articles Source Type: research
Tobacco Cessation May Improve Lung Cancer Patient Survival
Conclusions: Tobacco cessation among lung cancer patients after diagnosis may increase overall survival. (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - June 25, 2015 Category: Cancer & Oncology Tags: Original Articles Source Type: research
Hormone Use, Reproductive History, and Risk of Lung Cancer: The Women’s Health Initiative Studies
Conclusions: Indirect measures of estrogen exposure to lung tissue, as used in this study, provide only weak evidence for an association between reproductive history or HT use and risk of lung cancer. More detailed mechanistic studies and evaluation of risk factors in conjunction with estrogen receptor expression in the lung should continue as a role for estrogen cannot be ruled out and may hold potential for prevention and treatment strategies. (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - June 25, 2015 Category: Cancer & Oncology Tags: Original Articles Source Type: research
The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer
Conclusions: Recommended changes are as follows: to subclassify T1 into T1a (≤1 cm), T1b (>1 to ≤2 cm), and T1c (>2 to ≤3 cm); to subclassify T2 into T2a (>3 to ≤4 cm) and T2b (>4 to ≤5 cm); to reclassify tumors greater than 5 to less than or equal to 7 cm as T3; to reclassify tumors greater than 7 cm as T4; to group involvement of main bronchus as T2 regardless of distance from carina; to group partial and total atelectasis/pneumonitis as T2; to reclassify diaphragm invasion as T4; and to delete mediastinal pleura invasion as a T descriptor. (Source: Journal of Thoracic Oncology)
Source: Journal of Thoracic Oncology - June 25, 2015 Category: Cancer & Oncology Tags: IASLC Staging Committee Article Source Type: research
